Steroid reduction with efgartigimod in older adults with generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests if a new drug called efgartigimod can help older adults with generalized myasthenia gravis safely reduce their steroid dose. The goal is to manage the disease with fewer steroid side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You have generalized myasthenia gravis with a positive antibody test (AChR-Abs).
- You have been taking a moderate or high daily dose of steroids (like prednisone) for at least three months without changing the dose.
- You have developed at least one steroid-related health problem, such as type 2 diabetes, high blood pressure, being overweight, sleep issues, or irritability.
- You have not had certain treatments (like complement blockers or rituximab) recently, and you are not currently on a live vaccine or have a serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Hear when a new Myasthenia Gravis, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.